Blog & Resources Camargo Blog December 23rd, 2008

What is a ‘483?

You may read in the news or a company press release that a manufacturing site has received a ‘483. This is usually considered bad news. Indeed, failure to remedy observations in a ‘483 can lead to withheld product approvals or even plant closure.

When the FDA makes a visit to inspect a facility (manufacturer, lab, supplier, etc.) the inspector is looking for compliance with cGMP. Significant observations are recorded on FDA Form 483 (often shortened to 483 or ‘483). An overall summary of the inspection is recorded in an Establishment Inspection Report, EIR for short. Thus, an EIR is always given and a ‘483 may or may not be given, depending on what is found.

The facility’s management has to respond to a ‘483 – what it is going to do to fix the problem(s) and when they will be fixed. The FDA will decide if the plan is acceptable. Significant deviations may prompt FDA to come back at a later date to see if the planned fixes were implemented.

Where does the ‘483 come into play for product approval? During the review of an NDA or ANDA, the CMC reviewer requests input from FDA field operations to see if the manufacturing site, labs, suppliers, etc. have had acceptable inspections. This is know as Pre-Approval Inspection, or PAI for short. Once the field gives the okay and any CMC review issues are closed successfully, then the CMC review may finish and then the approval decision can be made.

The field operations may decide that it needs to inspect. The field is under no hurry to get their work done, they are not subject to PDUFA. If ‘483 observations are made, the company has to propose a remedy plan. The field may or may not agree to the proposed fixes or the timeline or both. Then the company has to wait for the field to get back to them and then respond appropriately, if it can. From my discussion, the reader should understand that the time for the field clearance is unpredictable by either the company or the review division.

To avoid ‘483’s delaying your product approval, your site(s) should undergo training and a mock PAI. This work should be outsourced to a third party to minimize bias.

For more information see: Inspection Overview

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights